Table 1.
Study Characteristics by Trial Number
| GSK Trial Number (Alternate GSK study identifier) | Study Sites | Study Phase | Age at Dose 1, wk | Vaccinated, No. | Follow-up, No. | Publication of Trial Results | |
|---|---|---|---|---|---|---|---|
| Year 1 | Year 2 | ||||||
| 107 625 (Rota-056) | Japan | 3 | 6–14 | 492 | 34 | 34 | Kawamura et al [22] |
| 102 247 (Rota-036) | Czech Republic, Finland, France, Germany, Italy, Spain | 3 | 6–14 | 2613 | 786 | 783 | Vesikari et al [23] |
| 102 248 (Rota-037) | Malawi, South Africaa | 3 | 5–10 | 2803 | 2268 | 1555 | Madhi et al [24] |
| 113 808 (Rota-075) | China | 3 | 6–16 | 1518 | 390 | 373 | Li et al [25] |
| 444 563/007 (Rota-007) | Singapore | 2 | 11–17 | 1737 | 447 | 441 | Phua et al [26] |
| 444 563/004 (Rota-004) | Finland | 2 | 6–12 | 249 | 209 | 204 | Vesikari et al [27] |
| 444 563/005 (Rota-005) | Canada, United States | 2 | 6–12 | 372 | 257 | 168 | Dennehy et al [28] |
| 444 563/006 (Rota-006) | Brazil, Mexico, Venezuela | 2 | 6–12 | 1498 | 425 | 273 | Salinas et al [29] |
| 444 563/013 (Rota-013) | South Africaa | 2 | 5–10 | 337 | 258 | 88 | Steele et al [30] |
| Total | 11 619 | 5074 | 3919 |
Abbreviation: GSK, GlaxoSmithKline.
aCountries categorized as high child mortality include Malawi and South Africa. Countries categorized as low child mortality include Brazil, Canada, China, Czech Republic, Finland, France, Germany, Italy, Japan, Mexico, Singapore, Spain, United States, and Venezuela.